Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors

This publication has 18 references indexed in Scilit:

• Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.
  Circulation, 1994
• Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
  New England Journal of Medicine, 1994
• Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
  BMJ, 1994
• Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab thrombolytic therapy: Results of the thrombolysis and angioplasty in mycardial infaraction (TAMI) 8 pilot study
  Journal of the American College of Cardiology, 1993
• The thrombin receptor extracellular domain contains sites crucial for peptide ligand-induced activation.
  Journal of Clinical Investigation, 1993
• Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation.
  Journal of Clinical Investigation, 1992
• Aspirin (75 mg/day) after an episode of unstable coronary artery disease: Long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization
  Journal of the American College of Cardiology, 1991
• Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
  Cell, 1991
• Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agentsa
  Annals of the New York Academy of Sciences, 1991
• Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina
  New England Journal of Medicine, 1983